Milmed Unico AB have filed a new patent application the 30th of June. The patent is for Treatment of inflammation. In vitro studies at Sapienza University have given significant results. In vivo studies will be performed and first study will focus on IBS ( Irritable Bowel Syndrome.
Master agreement signed with Medicorent and Startup Pharma. Medicorent provides CRO and regulatory services. Startup Pharma provides services internationally regarding new establishments of health products and has reputable contacts with companies in several countries.
Production agreement signed with Orkla (Jästbolaget) and Orkla will produce the dry product on a large scale during Q2.
The Swedish patent application for treatment of allergic disorders is approved, October 7th 2020. SE Pat. Nr.543 316
An article is published in the scientific journal Journal of Immunology and Allergy. It is about a study of people with various allergic disorders where one group received treatment of treated Milmed, and the other group received untreated Milmed. Scientific article name: Milmed Treatment Alleviates Symptoms of Allergy and Improves General Health